Phio Pharmaceuticals Corp. to Showcase INTASYL Technology at CAR-TCR Summit
Brief Summary
Phio Pharmaceuticals Corp. is set to showcase its INTASYL RNAi technology at the 9th CAR-TCR Summit in Boston, designed to enhance the effectiveness of cell therapies in cancer treatment, by silencing genes specific to solid tumors Zhitong+ 2.
Event Analysis
Product Introduction
Phio Pharmaceuticals Corp. has developed an innovative INTASYL RNAi technology platform aimed at improving the effectiveness of immune cells in killing tumor cells. This proprietary technology, INTASYL, is capable of silencing nearly any gene within the human genome with precision, thus providing a flexible solution for enhancing cell potency and improving overall yield in cancer treatments Press Releases+ 2.
Release and Presentation
The INTASYL technology will be showcased at the 9th CAR-TCR Summit, an event that took place on September 17, 2024, at the Hynes Convention Center in Boston. This event represents a significant platform for Phio to present its advancements in gene silencing technology to a specialized audience focused on cell therapy applications Zhitong.
Company Background
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company, publicly traded under NASDAQ: PHIO. It focuses on developing its proprietary INTASYL technology to address critical needs in the oncology sector, specifically through enhancing the effectiveness of cell-based therapies Press Releases+ 2.
Future Outlook
The presentation of INTASYL at the CAR-TCR Summit is expected to bolster Phio’s position in the market as a leader in innovative cancer treatments. The technology’s ability to target solid tumors and improve the application of cell therapies positions Phio favorably in terms of future business goals and market expectations Zhitong+ 2.
Market Reaction and Potential Impact
By effectively enhancing cell therapy applications, Phio’s technology has the potential to significantly impact the market for cancer treatments, offering more efficient methods for gene silencing and therapy enhancement. This could lead to increased interest from investors and partners looking at strategic collaborations to further commercialize and distribute these solutions Press Releases.
